KDR and cholangiocarcinoma: used a combination of ramucirumab and pembrolizumab in 26 patients with pre-treated advanced cholangiocarcinoma, suggested that the important role of the dual inhibition of the PD-1 and VEGFR pathways, the median PFS around 1.5 months and an 11.3 months median OS (27).